INY-03-041 (trihydrochloride)

INY-03-041 trihydrochloride is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive AKT inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003) . INY-03-041 trihydrochloride inhibits AKT1, AKT2 and AKT3 with IC50s of 2.0, 6.8 and 3.5 nM, respectively[1].

Product Specifications

UNSPSC

12352005

Target

Akt; PROTACs

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; PROTAC

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/iny-03-041-trihydrochloride.html

Purity

99.78

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C(N(CC1=C2C=CC=C1CCCCCCCCCCNC[C@H](C3=CC=C(Cl)C=C3)C(N4CCN(C5=C([C@H](C)C[C@H]6O)C6=NC=N5)CC4)=O)C2=O)CC7)NC7=O.Cl.Cl.Cl

Molecular Formula

C44H59Cl4N7O5

Molecular Weight

907.80

References & Citations

[1]You I, et al. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling. Cell Chem Biol. 2020 Jan 16;27 (1) :66-73.e7. |[2]Maira SM, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012 Feb;11 (2) :317-28.